C4 Therapeutics director granted 62,000 stock options

C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock.

Rhea-AI Filing Summary

C4 Therapeutics director Stephen Fawell was granted stock options linked to 62,000 shares of common stock. The options carry an exercise price of $4.25 per share and expire on June 23, 2036. This is a compensation-related award, not an open-market purchase.

The option grant vests and becomes exercisable in full on the earlier of June 24, 2027 or the next annual meeting of stockholders, as long as he continues serving on the Board. Following this grant, he holds options covering 62,000 shares directly.

Insider Trade Summary

Grant/Award: 62,000 shares

Grant/Award 1 txn

Insider Fawell Stephen

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	62,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 62,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Key Figures

Option grant size: 62,000 shares Exercise price: $4.25 per share Expiration date: June 23, 2036 +2 more

5 metrics

Option grant size 62,000 shares Stock Option (Right to Buy) underlying common stock

Exercise price $4.25 per share Conversion/exercise price of granted options

Expiration date June 23, 2036 Option term end date

Shares after transaction 62,000 options Total derivative shares following transaction

Vesting date trigger June 24, 2027 Earlier of this date or next annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.2500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Board financial

"subject to the recipient's continued service as a member of the Board on such date"

A board is a group of elected people who oversee a company’s direction and management, like a steering committee that hires and evaluates the CEO, approves major deals, and sets broad policies. Investors care because the board’s decisions and oversight shape strategy, risk, dividend and takeover decisions, and legal protections for shareholders—so a strong, independent board can increase the chances of steady returns and protect against mismanagement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stephen Fawell receive in this C4 Therapeutics (CCCC) Form 4?

Stephen Fawell received a grant of stock options covering 62,000 shares of C4 Therapeutics common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price and term of Stephen Fawell’s CCCC stock options?

The granted options have an exercise price of $4.25 per share and expire on June 23, 2036. This long-dated term allows substantial time for potential exercise if vesting conditions are met and Mr. Fawell chooses to exercise.

When do Stephen Fawell’s new C4 Therapeutics options vest?

The options vest and become exercisable in full on the earlier of June 24, 2027 or the next annual meeting of C4 Therapeutics stockholders. Vesting is conditioned on his continued service as a member of the Board through that date.

Is Stephen Fawell buying or selling CCCC shares in this Form 4?

This Form 4 reports an option grant, not a stock purchase or sale in the open market. The transaction is coded as a grant or award acquisition, providing rights to buy shares later rather than an immediate share transaction.

How many C4 Therapeutics shares are covered by Stephen Fawell’s options after this grant?

After this transaction, Stephen Fawell holds stock options covering 62,000 shares of C4 Therapeutics common stock. These options are held directly and become exercisable only once the specified vesting conditions are satisfied in the future.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fawell Stephen

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.25	06/24/2026		A		62,000		(1)	06/23/2036	Common Stock	62,000	$0	62,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)